Terry Ann Fortin

Journal Article Genome Med · May 10, 2021 BACKGROUND: Pulmonary arterial hypertension (PAH) is a lethal vasculopathy characterized by pathogenic remodeling of pulmonary arterioles leading to increased pulmonary pressures, right ventricular hypertrophy, and heart failure. PAH can be associated with ... Full text Link to item Cite

Planned Initiation of Venoarterial Extracorporeal Membrane Oxygenation Prior to Liver Transplantation in a Patient With Severe Portopulmonary Hypertension.

Journal Article Liver Transpl · May 2021 Full text Link to item Cite

United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics.

Journal Article Chest · January 2021 BACKGROUND: The treatment, genotyping, and phenotyping of patients with World Health Organization Group 1 pulmonary arterial hypertension (PAH) have evolved dramatically in the last decade. RESEARCH QUESTION: The United States Pulmonary Hypertension Scient ... Full text Link to item Cite

Treatment-related biomarkers in pulmonary hypertension patients on oral therapies.

Journal Article Respir Res · November 19, 2020 BACKGROUND: Multiple classes of oral therapy are available for the treatment of pulmonary arterial hypertension (PAH), but there is little to guide clinicians in choosing a specific regimen or therapeutic class. We aimed to investigate whether treatment-re ... Full text Open Access Link to item Cite

Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.

Journal Article J Cardiovasc Pharmacol · April 2020 Parenteral prostacyclin therapies remain first-line therapy for patients with pulmonary arterial hypertension (PAH) with class IV symptoms. In selected patients who have been clinically stabilized, switching to selexipag, a chemically distinct prostacyclin ... Full text Open Access Link to item Cite

Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension.

Journal Article Sci Rep · March 11, 2019 The presence of pulmonary hypertension (PH) significantly worsens outcomes in patients with advanced sarcoidosis, but its optimal management is unknown. We aimed to characterize a large sarcoidosis-associated pulmonary hypertension (SAPH) cohort to better ... Full text Open Access Link to item Cite

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.

Journal Article Lancet Respir Med · March 2019 BACKGROUND: Rare genetic variants cause pulmonary arterial hypertension, but the contribution of common genetic variation to disease risk and natural history is poorly characterised. We tested for genome-wide association for pulmonary arterial hypertension ... Full text Link to item Cite

Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.

Journal Article J Heart Lung Transplant · January 2019 BACKGROUND: A long-term trial showed that the oral prostacyclin (PGl2) receptor (IP) agonist, selexipag, delayed disease progression in patients with pulmonary arterial hypertension (PAH). Transition to selexipag in patients treated with more burdensome in ... Full text Link to item Cite

Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension.

Journal Article J Cardiovasc Pharmacol · April 2016 Pulmonary arterial hypertension (PAH) has emerging therapeutic options including prostacyclin analogs. Inhaled therapy offers advantages compared with alternative routes of administration. We aimed to determine the safety and tolerability of inhaled trepro ... Full text Link to item Cite

Comprehensive assessment of right ventricular function in patients with pulmonary hypertension with global longitudinal peak systolic strain derived from multiple right ventricular views.

Journal Article J Am Soc Echocardiogr · June 2014 BACKGROUND: Right ventricular (RV) function is a strong predictor of mortality in pulmonary hypertension (PH), but two-dimensional (2D) echocardiography-derived assessments of RV function that could aid in risk assessment and management of patients with PH ... Full text Link to item Cite

Cardiac imaging impaired by a silicone breast implant.

Journal Article Clin Nucl Med · April 2005 The authors report a case of a left-sided silicone breast implant interfering with nuclear imaging of the myocardium. Cardiac SPECT imaging of a woman documented widespread infarct in the anterolateral, inferior, and posterolateral walls, as well as mixed ... Full text Link to item Cite

Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Journal Article Chest · July 2004 Although idiopathic pulmonary arterial hypertension is perceived as a progressive disease with a uniformly poor outcome, the natural history of disease is heterogeneous, with some patients dying within months of diagnosis and others living for decades. The ... Full text Link to item Cite

Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Journal Article Chest · July 2004 Pulmonary arterial hypertension (PAH) occurs as an idiopathic process or as a component of a variety of disease processes, including chronic thromboembolic disease, connective tissue diseases, congenital heart disease, and exposure to exogenous factors inc ... Full text Link to item Cite

Accuracy and limitations of planar thallium scintigraphy for identifying the involved coronary artery in patients with single-vessel disease: Findings in the ACME trial

Journal Article Cardiovascular Reviews and Reports · January 1, 2001 This study compared the location of thallium-201 perfusion defects with the location of angiographically documented single-vessel coronary artery stenosis in 161 patients enrolled in the Veterans Administration Cooperative Study of Angioplasty Compared to ... Cite

TIMI frame count: a quantitative method of assessing coronary artery flow.

Journal Article Circulation · March 1, 1996 BACKGROUND: Although the Thrombolysis in Myocardial Infarction (TIMI) flow grade is valuable and widely used qualitative measure in angiographic trials, it is limited by its subjective and categorical nature. METHODS AND RESULTS: In normal patients and pat ... Full text Link to item Cite

A comparison of quality of life scores in patients with angina pectoris after angioplasty compared with after medical therapy. Outcomes of a randomized clinical trial. Veterans Affairs Study of Angioplasty Compared to Medical Therapy Investigators.

Journal Article Circulation · October 1, 1995 BACKGROUND: Evaluations of therapy for the treatment of angina have traditionally consisted of a combination of objective measures, such as exercise tolerance, and subjective markers, such as angina attack rate. Recently, the need to assess "how patients f ... Full text Link to item Cite

Relation between coronary artery stenosis assessed by visual, caliper, and computer methods and exercise capacity in patients with single-vessel coronary artery disease. The Veterans Affairs ACME Investigators.

Journal Article Circulation · May 1994 BACKGROUND: Practitioners often assume a close relation between angiographic coronary artery stenosis and patient functional capacity. To test this unproven hypothesis, we analyzed the relation between coronary artery stenosis measured by different methods ... Full text Link to item Cite